Basis of Presentation (Details) $ / shares in Units, $ in Thousands		3 Months Ended
	Feb. 20, 2020 USD ($) contingent_value_right $ / shares shares	Mar. 31, 2021 USD ($) day $ / shares shares	Dec. 31, 2020 USD ($) $ / shares	Jun. 19, 2020 USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Contingent consideration liabilities		$ 17,000	$ 15,800
Business combination, consideration transferred, equity interests issued (in shares) | shares		26,844,877
Business combination common stock under contingent value right (in shares) | shares		86,630,633
Maximum
Business Acquisition [Line Items]
No of working days | day		5
Minimum
Business Acquisition [Line Items]
No of working days | day		4
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares) | shares	0.31
Percentage of net sales, contingent consideration	40.00%
Contingent consideration liabilities				$ 3,700
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration	$ 100,000
Number of CVRs | contingent_value_right	1
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 150,000